Brief: Lilly gets civil investigative demand from Minnesota AG for insulin product pricing
28/07/2017 16:48
July 28 (Reuters) - Eli Lilly And Co LLY.N :
* Says got civil investigative demand from Minnesota's
office of Attorney General relating to pricing, sale of insulin
products - SEC filing
* Says offices of attorneys general in California and
Florida have requested information relating to pricing of
company's insulin products
* Says lost patent exclusivity for Strattera in the U.S. in
May 2017, and generic versions of Strattera were approved in the
same month
* Entry of generic versions of Strattera has caused "rapid
and severe" decline in revenue, which will have material adverse
effect on results
* In May, Japanese Patent Office resumed 1 of 2 remaining
demands for invalidation of company's two vitamin regimen
patents, brought by Nipro Corp
Source text - (http://bit.ly/2w6xEZd)
Further company coverage: LLY.N
((Bangalore.newsroom@thomsonreuters.com;))